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COX-2 and MMP-9 have been reported to show an overexpression in pancreatic cancer, and thus an attempt to explore the
correlation between them has become a target of this study. Besides, PGE2, a product of COX-2, was also under research as to
whether it is involved in the upregulation of MMP-9 expression by COX-2. Expression of COX-2 and MMP-9 mRNA varied in
pancreaticadenocarcinomas,andthemRNAlevelofCOX-2wascorrelatedpositivelywithMMP-9.BothBxPC-3andCapan-1cells
had strong expression of COX-2 and MMP-9. MMP-9 expression was downregulated signiﬁcantly in BxPC-3 and Capan-1 cells
after treatment with COX-2 inhibitors or COX-2 siRNA plasmids, and upregulated in BxPC-3 signiﬁcantly by exogenous TNF-α,
LPS or PGE2. The upregulation of MMP-9 by TNF-α or LPS was inhibited by COX-2 inhibitor NS398. There was a signiﬁcant
increase in the migration of BxPC-3 cells with TNF-α,L P S ,o rP G E 2 treatment; however, the increase caused by TNF-α or LPS was
also inhibited remarkably by NS398. Our ﬁndings demonstrated that COX-2 upregulates MMP-9 expression in pancreatic cancer,
and PGE2 may be involved in it.
1.Introduction
Overexpression of cyclooxygenase-2 (COX-2) has been
f o u n di nas e r i e so fh u m a nc a n c e r s[ 1–7], which suggests its
linkage to the development of these tumours. Speciﬁcally, its
action in carcinogenesis is generally thought to be mediated
by COX-2-generated prostanoids, especially prostaglandin
E2 (PGE2), the most abundant prostanoid in human body,
by stimulating cell proliferation, invasion, and angiogenesis
[8–13]. Several other studies demonstrate an overexpression
o fC O X - 2i np a n c r e a t i cc a n c e r[ 14–16]a n das u p p r e s s i o no f
COX-2 inhibitors on the proliferation [17].
Pancreatic cancer, one of the most lethal malignancies,
is usually diagnosed when perineural invasion and distal
metastasis are already present. However, mechanisms of the
initial phase are so far not completely understood. Though
thecorrelationofCOX-2expressionwithperineuralinvasion
in pancreatic cancer patients has been generally examined
[18], the exact process remains unclear and still needs to pin
down.
Matrix metalloproteinases (MMPs), as zinc containing
enzymes, are labelled the agent to degrade extracellular
matrix components and to play a crucial role in invasion
and metastasis of cancer cells. MMP-9 from the family is
constantly upregulated in a variety of human cancers, and
this has aroused our interest to investigate the correlation
of COX-2 with MMP-9 in pancreatic cancer. Likewise, the
involvement of PGE2 (as a product of COX-2) in the
upregulationofMMP-9expressionbyCOX-2wasalsounder
research.
2. Methods
2.1. Pancreatic Cancer Cell Lines and Tissue Specimens. The
human pancreatic cancer cell lines BxPC-3, Capan-1, PANC-
1, and AsPC-1 were obtained from ATCC (Rockville, MD,
USA) and were cultured in RPMI 1640 supplemented with
10% fetal bovine serum, at 37◦Ci nah u m i di n c u b a t o r
with 5% CO2. 16 pancreatic adenocarcinoma specimens
were acquired from patients under operation with all their
informed consent at Shengjing hospital, Chinese Medical
University and were frozen in liquid nitrogen immediately
after surgical removal. This study was carried out with2 Gastroenterology Research and Practice
the approval of the ethical committee of China Medical
University.
2.2. RT-PCR and Real-Time PCR. Total RNA was isolated
from tissues and cell lines by Trizol (Takara, Dalian, China)
according to the protocol supplied by the manufacturers.
Then, 1μg of RNA was used to synthesize ﬁrst-strand cDNA.
RT-PCRwascarriedoutbyTakaraRNAPCR3.0Kit(Takara,
Dalian, China). Real-time PCR was performed using the
LightCycler system together with the LightCycler DNA Mas-
terSYBRGreenIKit(RocheDiagnostics).Thehousekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal control. Gene expression was
quantiﬁed by the comparative CT method, normalizing
CT values to GAPDH and calculating relative expression
values.Primersequenceswereasfollows:COX-2forward,5 -
ACAATGCTGACTATGGCTAC-3 ,r e v e r s e ,5  -CTGATG-
CGTGAAGTGCTG-3 ; MMP-9 forward, 5 -AGGACGGCA-
ATGCTGATG-3 ,r ev e rse,5  -TCGTAGTTGGCGGTGGTG-
3 ; GAPDH forward, 5 -GGGAAACTGTGGCGTGAT-3 ,
reverse, 5 -AAAGGTGGAGGAGTGGGT-3 .
2.3. Western Blotting. Cell lysates were prepared with sample
buﬀer (50mmol/L Tris-HCl (pH 6.8), 100mmol/L DTT, 2%
SDS, 0.1% bromophenol blue, and 10% glycerol) and were
subjectedtoa12% sodium dodecyl sulfate(SDS)/acrylamide
gel. The proteins on acrylamide gel were transferred to a
nylon membrane, which was blocked overnight (4◦C in PBS
with0.1%Tweenand10%milkpowder).Primaryantibodies
for COX-2 and MMP-9 (Santa Cruz, CA, America), and
the corresponding secondary antibodies (Santa Cruz, CA,
America) were applied before immunoblotting. The human
gene β-actin (Santa Cruz, CA, America) was used as an
internal control. Blots were visualized with FX pro plus
system (Bio-Rad) and quantiﬁed using Scion Image 4.03
software.
2.4. RNA Interference. COX-2 siRNA plasmid and nonsi-
lencing control siRNA plasmid were purchased from Takala
(Dalian, China). Cells were seeded into a 24-well plate at
a density of 2 × 105. On the following day, cells were
transfected with COX-2 siRNA or control siRNA using Lipo-
fectamine 2000 (Invitrogen, United Kingdom) according to
the manufacturer’s instructions.
2.5. Elisa for PGE2 in Cell Culture Supernatants. Concentra-
tions of PGE2 in cell culture supernatants were measured
using the Quantikine Elisa kit (Boster, Wuhan, China)
according to the manufacturer’s instructions. The sensitivity
of the assay was 2pg/mL.
2.6. Migration Assays. The migration of cultured cells was
assayed using Matrigel invasion chamber (24-well format,
8μm pore; BD pharmingen). Cells (5 × 105)w e r ea d d e dt o
the upper chamber. After 24 hours at 37◦C and 5% CO2,
migrated cells on the lower surface were stained using 1%
toluidine blue after ﬁxation with 100% methanol. For each
transwell, the number of migrated cells in 10 ﬁelds (×200)
was counted.
2.7. Statistical Analysis. Correlation between COX-2 expres-
sion and MMP-9 expression in pancreatic cancer speci-
mens was analyzed using Spearman’s rank correlation test.
Expression of mRNA was compared by Student’s t-test in
pancreatic cell lines. Statistical analysis was carried out using
SPSS version 11.0 (SPSS, Chicago, IL, USA). Diﬀerence was
considered signiﬁcant when P-value was <0.05.
3. Results
3.1. Expression of COX-2 and MMP-9 mRNA in Pancreatic
Cancers. COX-2 and MMP-9 mRNA were initially detected
in 16 pancreatic adenocarcinomas by RT-PCR, and then
their expression was found to have varied in these cancers
(Figure 1). In an attempt to evaluate the presumed correla-
tion of COX-2 mRNA expression with MMP-9, we further
determined their mRNA level using real-time PCR, and as
hypothesized, Spearman’s rank correlation test veriﬁed a
positive one in overall 16 pancreatic cancers (P<0.01,
Figure 1).
3.2. Diﬀerential Expression of COX-2 and MMP-9 in Pancre-
atic Cancer Cell Lines. Western blotting was used to examine
COX-2 and MMP-9 expression in pancreatic cell lines BxPC-
3, Capan-1, PANC-1, and AsPC-1, and the examination
showed COX-2 (72kDa) and MMP-9 (92kDa) expression
varied in these cells. Both BxPC-3 and Capan-1 cells had
strong expression of COX-2 and MMP-9, both of which,
however, presented a weak expression in PANC-1 cells. No
COX-2 expression was found in AsPC-1 cells (Figure 2).
By Elisa we further revealed PGE2 protein in the culture
supernatant in BxPC-3 and Capan-1 cells (Figure 2).
3.3. Inhibition of MMP-9 Expression by COX-2 Inhibitors.
In an attempt to explore the involvement of COX-2 in
the upregulation of MMP-9, we treated particularly BxPC-
3 and Capan-1 cells with selective COX-2 inhibitor NS398
(Sigma, 100μmol/L) for 24 hours, and we found MMP-
9 expression was downregulated signiﬁcantly in these cells
(P<0.01, resp., Figure 3). Similar results were observed
when a nonselective COX-2 inhibitor indomethacin (Sigma,
100mmol/L) was employed following the same procedure
(P<0.01, resp., Figure 3). In addition, it was found
both BxPC-3 and Capan-1 secreted less PGE2 protein after
treatment with NS398 for 12 hours (P<0.01, resp.) or 24
hours (P<0.01, resp., Figure 3).
3.4. Downregulation of MMP-9 by COX-2 siRNA. COX-2
siRNA plasmid was used to transfect BxPC-3 and Capan-
1 cells, and correspondingly nonsilencing siRNA plasmid
was employed in the counterpart as control. It was observed
that expression of COX-2 was absent in BxPC-3 and Capan-
1 after transfection with COX-2 siRNA plasmid (Figure 4).
ThenexpressionofMMP-9wasdetectedbyWesternblotand
real-time PCR, and it was noted in the detection that, afterGastroenterology Research and Practice 3
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Figure 1: Expression of COX-2 and MMP-9 mRNA in pancreatic
cancers. (a) Expression of COX-2 and MMP-9 mRNA was detected
in 16 pancreatic cancers by RT-PCR. (b) Level of MMP-9 mRNA
wascorrelatedpositivelywiththatofCOX-2mRNAin16pancreatic
cancers by real-time PCR, P<0.01.
transfection with COX-2 siRNA plasmid, MMP-9 expression
was downregulated signiﬁcantly in BxPC-3 and Capan-
1cells, compared with cells with control siRNA (P<0.001,
resp.) or cells without siRNA (P<0.001, resp.) (Figure 4).
3.5. Involvement of COX-2 in the Upregulation of MMP-9
by TNF-α and LPS. BxPC-3 cells were treated with TNF-α
(Sigma, 100ng/mL) or LPS (Sigma, 100ng/mL) for 6 hours
in attempt to further explore the role of COX-2 in the
upregulation of MMP-9 expression, and real time-PCR and
Western blotting detection revealed that both COX-2 (P<
0.01, resp.) and MMP-9 (P<0.01, resp.) were upregulated
signiﬁcantly (Figure 5). The upregulation of MMP-9 by
TNF-α or LPS can be inhibited signiﬁcantly by NS398 (P<
0.01, resp.), however, the upregulation of COX-2 cannot be
inhibited by NS398 (Figure 5).
3.6. Upregulation of MMP-9 by Exogenous PGE2. To explore
whether PGE2 is involved in the upregulation of MMP-9
expression by COX-2, BxPC-3 cells were treated with 10, 50,
or 100μmol/L PGE2 (Sigma) for 6 hours. Real-time PCR and
Western blotting detection revealed MMP-9 was upregulated
signiﬁcantly in BxPC-3 cells treated with 50μmol/L (P<
0.01, Figure 6) or 100μmol/L (P<0.01, Figure 6).
3.7. Migration Assays. Migration analysis was performed
using the Matrigel invasion chamber in an attempt to
investigate whether the upregulated MMP-9 was functional.
There was a signiﬁcant increase in the migration of BxPC-
3 cells with TNF-α (P<0.001), LPS (P<0.001) or PGE2
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Figure 2: Expression of COX-2 and MMP-9 in pancreatic cancer
cell lines. (a) Expression of COX-2 and MMP-9 was detected in
pancreatic cell lines BxPC-3, Capan-1, PANC-1, and AsPC-1 by
Western blotting. (b) PGE2 protein in the culture supernatant
of BxPC-3 and Capan-1 cells was measured by Elisa. Data are
expressed as mean ± SD, n = 3.
(P<0.001) treatment in the upper chamber, compared
with control cells without treatment (Figure 7). Later on,
however, the increase caused by TNF-α or LPS was inhibited
remarkably when NS398 was added (P<0.01, resp.,
Figure 7). The increase caused by PGE2 was unchanged.
4. Discussion
COX-2 shares catalytic activity and a 60% sequence homol-
ogy with COX-1, another isoform of cyclooxygenase (COX).
Though, unlike COX-1, COX-2 was not found to be
expressed in most tissues in physiologic conditions, and
it can be induced rapidly by some stimuli, such as LPS,
cytokines, and growth factors [19, 20]. COX-2 and COX-
1 catalyze the conversion of arachidonic acid to PGG2 and
PGH2, which can subsequently be converted into PGE2 by
PGE synthase. Under normal conditions, PGE2 is thought
to be involved in some physiological functions including
protection of gastric mucosa and regulation of glomerular
ﬁltration, whereas excessive production of PGE2 is respon-
sible for some inﬂammatory diseases, such as rheumatoid
arthritis and osteoarthritis. PGE2 in central nervous system4 Gastroenterology Research and Practice
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Figure 3: Inhibition of MMP-9 expression by NS398 or indomethacin (a) and (b) MMP-9 expression was inhibited in BxPC-3 and Capan-
1 cells after treatment with NS398 (∗P<0.01, resp., versus control ) or indomethacin (∗P<0.01, resp., versus control). (c), (d) PGE2
protein levels were decreased in BxPC-3 and Capan-1 after treatment with NS398 for 12 hours (∗P<0.01, resp., versus control) or 24 hours
(∗P<0.01, resp., versus control). Data are expressed as mean ± SD, n = 3. NS: NS398; indo: indomethacin.
plays a key role in fever, one of the most common signs
of inﬂammatory diseases, and the decrease of its level by
inhibition of COX-2 expression can lead to a suppression of
the symptom.
COX-2 and PGE2 are also blamed for their role in human
cancer. Early evidence comes from studies on colorectal
cancer, where their levels were found elevated, and accord-
ingly, the COX-2 inhibitors helped to reduce the incidence
[21, 22]. In pancreatic cancer, COX-2 was also reported to be
overexpressed [14–16]. In contrast to the normal pancreatic
tissues, where COX-2 expression was only found in islet cells,
the cancer specimens show COX-2 expression was common
but varied in our present studies. It was also found present
in 3 of 4 pancreatic cancer cell lines, strong in BxPC-3 and
Capan-1 cells, and weak in PANC-1 cells, but none of it was
spotted in AsPC-1 cells. By Elisa we further revealed PGE2
protein in the culture supernatant in BxPC-3 and Capan-
1 cells. These results suggest COX-2/PGE2 pathway may be
involved in a part of the pancreatic cancer patients, though
the mechanisms of COX-2 upregulation remain unclear. It
is acknowledged that in inﬂammatory diseases, COX-2 is
induced by LPS or some cytokines, such as IL-1β and TNF-α
produced by some inﬂammatory cells, and therefore it could
be reasonably speculated that in tumors, the upregulation of
itmayalsobeattributedtoLPSandthesecytokines.Infact,it
was observed that LPS can stimulate some colon cancer cells
to express COX-2 and release PGE2 by activation of NF-κB
[23]. In this study, we found both LPS and TNF-α increaseGastroenterology Research and Practice 5
β-actin
MMP-9
COX-2
BxPC-3 Capan-1
siRNA No Control COX-2 No Control COX-2
(a)
∗
0
0.2
0.4
0.6
0.8
1
1.2
M
M
P
-
9
m
R
N
A
e
x
p
r
e
s
s
i
o
n
No siRNA
Control siRNA
COX-2 siRNA
∗∗
∗
∗∗
BxPC-3 Capan-1
(b)
Figure 4: Downregulation of MMP-9byCOX-2siRNA (a) Western
blotting revealed expression of COX-2 was absent in BxPC-3
and Capan-1 after transfection with COX-2 siRNA plasmid. (b)
After transfection with COX-2 siRNA plasmid, MMP-9 mRNA
expression was downregulated signiﬁcantly in BxPC-3 and Capan-
1 cells, compared with cells with control siRNA (∗P<0.001, resp.,
versus control siRNA) or cells without siRNA (∗∗P<0.001, resp.,
versus no siRNA). Data are expressed as mean ± SD, n = 3.
COX-2 expression in pancreatic cancer cells, which suggests
inﬂammatory microenvironment may be responsible for the
overexpression of COX-2 in some pancreatic cancers.
Inaddition tocellproliferationandtumorgrowth,COX-
2/PGE2 pathway is also involved in tumor invasiveness and
metastasis [24–26]. It was observed that COX-2 expression
increased invasiveness of colorectal cancers [27], and PGE2
boosted motility of colorectal cancer cells [28]. Furthermore,
PGE2 was found to regulate COX-2-dependent invasion and
metastasis of nonsmall cell lung cancer in an autocrine or
paracrine manner [29]. In pancreatic cancer, one study has
shown COX-2 expression was signiﬁcantly associated with
increased perineural invasion [18]. However, mechanisms
of increased invasiveness and metastasis caused by COX-
2/PGE2 are largely unknown. On the other hand, MMP-9,
one of the two types IV collagenases, was extensively studied
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Figure 5: Involvement of COX-2 in the upregulation of MMP-
9b yT N F - α and LPS. (a) Western blotting revealed expression
of COX-2 and MMP-9 was increased in BxPC-3 after treatment
with exogenous TNF-α or LPS. (b) COX-2 mRNA expression was
upregulated by TNF-α or LPS (∗P<0.01, resp., versus control).
NS398 had no eﬀect on the upregulation. (c) MMP-9 mRNA
expression was upregulated by TNF-α or LPS (∗P<0.01, resp.,
versus control). The upregulation was signiﬁcantly inhibited by
NS398. Data are expressed as mean ± SD, n = 3. NS: NS398.
in human cancer, and a large body of evidence indicates its
expression correlates well with tumor invasion and metas-
tasis. In fact, its overexpression was observed in pancreatic
cancers by several studies [30–32], and its levels were corre-
lated positively with motility and invasiveness of pancreatic
cancer cells. Consistent with these observations, our results
indicated MMP-9 expression is a common phenomenon in
pancreatic cancer, which can be regulated by a number of
factors, including some inﬂammatory stimuli. Our study
demonstrated that both LPS and TNF-α can upregulate it
andincreasetheinvasivenessofpancreaticcancercells.Taken6 Gastroenterology Research and Practice
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Figure 6: Upregulation of MMP-9 by exogenous PGE2 Western
blotting (a) and real-time PCR (b) revealed MMP-9 was upregu-
lated in BxPC-3 cells treated with 50μmol/L (∗P<0.01, versus
0μmol/L) or 100μmol/L (∗P<0.01, versus 0μmol/L). Data are
expressed as mean ± SD, n = 3.
together, we speculated that COX-2/PGE2 may increase cell
invasiveness and metastasis through MMP-9.
OurinitialﬁndingsrevealapositivecorrelationofmRNA
level of COX-2 expression with MMP-9 in pancreatic cancer
specimens, and a probable connection between them in
cancer cells. There was also strong expression of both agents
in BxPC-3 and Capan-1 cells, but a weak one in PANC-1
cells. Second, MMP-9 expression was downregulated signif-
icantly in BxPC-3 and Capan-1 cells after treatment with
COX-2inhibitorsortransfectionwithCOX-2siRNAplasmid
to abrogate COX2 expression. Third, their expression was
increased by pancreatic cancer cells due to exogenous TNF-α
and LPS but the elevated expression of MMP-9 was inhibited
by COX-2 inhibitor NS398 and was elevated again when
treated with exogenous PGE2. Finally, there was a signiﬁcant
increaseinthemigrationofBxPC-3cellswithTNF-α,LPSo r
PGE2 treatment, which, however, was inhibited remarkably
by NS398. Taken together, all lines of evidence suggest COX-
2/PGE2 pathwayis involved intheupregulationof MMP-9in
pancreatic cancer.
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Figure 7: Migration analysis. Migration of BxPC-3 cells was
increased after treatment with TNF-α (∗P<0.001, versus control),
LPS (∗P<0.001, versus control), or PGE2 (∗P<0.001, versus
control). The increase caused by TNF-α or LPS was inhibited
remarkably when NS398 was added (∗∗P<0.01, versus TNF;
∗∗∗P<0.01, versus LPS). Data are expressed as mean ± SD, n = 3.
NS: NS398.
COX-2 inhibitors have been shown to be eﬀective in
preventing colon cancer in animal models or clinical trials
[33, 34]. Furthermore, a chronic usage of them, according
to epidemiological studies, can decrease the incidence of
colorectal cancer. The inhibitors were also found to suppress
the development of pancreatic cancer in an animal model
[35]. Such antitumor eﬀects have been largely attributed
to a consequent reduction in PGE2 levels, as one study
showed, in culturedBxCP-3 cells,PGE2 levelsweredecreased
signiﬁcantly after treatment with indomethacin and NS398
(COX-2 inhibitors) [16]. Similar results were observed in
our study, which revealed that COX-2 inhibitors, either
selective or nonselective, decreased the PGE2 levels, reduced
MMP-9 production, and inhibited cell invasiveness. On
the other hand, exogenous PGE2 was found to increase
MMP-9 expression and cell invasiveness. All these ﬁndings
led to our conclusion that the eﬀects of COX-2 inhibitors
on pancreatic cancer cell invasiveness are primarily related
to COX-2/PGE2 pathway, though the possibility of other
mechanisms’ involvement can hardly be ruled out.
PGE2 in human cancer are not only blamed for cell
growth and proliferation, but also for the invasion and
metastasis. In fact, these eﬀects are mediated by the partic-
ular corresponding G-protein-coupled receptors (GPCRs) of
PGE2, named EP1, EP2, EP3, and EP4. Studies have shown
only EP4 is implicated in cell invasion and migration. For
instance, PGE2 was found to regulate COX-2-dependent
invasion and metastasis of nonsmall cell lung cancer via
the EP4 receptor signaling [29]. It is interesting that EP4
expression can also be regulated by LPS, just like PGE2.
However, it still remains unknown whether EP4 mediates
the action of PGE2 in pancreatic cancer, as its expression
status was not determined in our study. Hopefully, it may
oﬀer another eﬀective therapeutic target for these patients
with further thorough laboratory observations and concrete
ﬁndings.Gastroenterology Research and Practice 7
In conclusion, we have determined COX-2/PGE2 path-
way’s involvement in the upregulation of MMP-9 in pan-
creatic cancer, and the restraint of COX-2 inhibitors on
MMP-9expressionandcancercellinvasiveness.Theseresults
shedlightontheconnectionsbetweenCOX-2/PGE2 pathway
with tumor growth, as well as invasiveness and metastasis
in pancreatic cancer. With these important inﬂammatory
mediators exhibiting complex eﬀects in pancreatic cancer,
a further safe conclusion is that there is a tight link
between inﬂammation or inﬂammatory microenvironment
with pancreatic carcinogenesis.
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